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The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale
for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers
show that themolecular signature ofVHL/kidney cancers is profoundly influencedbywhether theyproduce
both HIF2a and HIF1a or HIF2a alone.People who are ‘‘lumpers’’ look for com-
monalities among seemingly disparate
entities, while people who are ‘‘splitters’’
looked for differences among seemingly
similar entities. In this issue of Cancer
Cell, Simon and coworkers (Gordan et al.,
2008) make a case for splitting clear
cell renal carcinomas into three groups
(Figure 1).
In 2008, over 50,000 Americans will be
diagnosed with cancer of the kidney and
renal pelvis, and over 13,000 will die of
this disease, making it one of the ten lead-
ing causes of cancer death in the United
States. Worldwide, over 250,000 new
cases are diagnosed each year.
Kidney cancers account for 95% of
cancer of the kidney and renal pelvis. Sur-
gery is the mainstay of treatment for early-
stage (organ-confined) kidney cancer and
is often curative in this setting. Unfortu-
nately, kidney cancers that cannot be re-
moved surgically, or that recur after initial
attempts at surgical resection, are usually
fatal. A small subset of patients with ad-
vanced kidney cancers experience dura-
ble remissions after treatment with high-
dose interleukin-2. Unfortunately, this
therapy is very toxic, and it is impossible
to predict which patients will benefit. Kid-
ney cancer is refractory to conventional
forms of chemotherapy and radiotherapy.
In fact, until recently, it was ethical to
include a placebo arm in randomized clin-
ical trials of new agents for advanced
kidney cancer patients who had failed or
were not eligible for immunostimulants
such as interleukin-2.
Clear cell renal carcinomas (ccRCCs)
account for 75% of all kidney cancers.
Individuals with von Hippel-Lindau (VHL)
tumor suppressor gene germline muta-
tions have an increased risk of developing
ccRCC and biallelic VHL inactivation, dueto somatic mutations or, less frequently,
promoter hypermethylation, occurs in
50%–75% of sporadic ccRCCs. More-
over, restoration ofVHL function inVHL/
renal carcinomas suppresses tumor
growth. In short, VHL inactivation plays
a causal role in hereditary and sporadic
ccRCC.
Among its many functions, the VHL
gene product, pVHL, is the substrate rec-
ognition component of a ubiquitin ligase
that inhibits the transcription factor hyp-
oxia-inducible factor (HIF), which consists
of an unstable a subunit and a stable
b subunit (Kaelin, 2008). Specifically, the
pVHL complex targets the HIFa subunit
for destruction when oxygen is present.
Accordingly,VHL/ kidney cancers over-
produce HIF and HIF-responsive gene
products such as VEGF. Drugs that inhibit
VEGF or its receptor KDR have now dem-
onstrated significant activity in the treat-
ment of kidney cancer, as have mTOR
inhibitors, which indirectly downregulate
HIF (Kaelin, 2008).
Humans have three HIFa genes. HIF1a
and HIF2a are both capable of activating
transcription. Whether HIF3a activates
transcription is less clear, and certain
HIF3a isoforms are dominant-negative in-
hibitors with respect to HIF1a and HIF2a.
HIF1a is ubiquitously expressed, while
HIF2a expression is more restricted. For
this and other historical reasons, HIF1a
has been the most intensively studied HIF
family member. Nonetheless, important
quantitative and qualitative differences
are beginning to emerge between HIF1a
and HIF2a.
One difference is that the genes acti-
vated by HIF1a and HIF2a are overlap-
ping but not entirely congruent (Kaelin
and Ratcliffe, 2008). For example, HIF1a
plays a particularly important role in theCancer Cell 14,activation of genes involved in glucose
metabolism, while HIF2a has been linked
to the induction of genes such as the stem
cell factor gene Oct4 and the erythropoi-
etic hormone gene erythropoietin (EPO).
HIF1a can, both directly and indirectly,
cooperate with or antagonize c-Myc in
a context-dependent manner (Kaelin and
Ratcliffe, 2008). Importantly, HIF2a coop-
erates with c-Myc and promotes cell
proliferation under conditions in which
HIF1a antagonizes c-Myc (Gordan et al.,
2007). The biochemistry underlying these
various differences is incompletely under-
stood but might include differential sensi-
tivity to FIH1, an asparaginyl hydroxylase
that hydroxylates and thereby silences
one of HIFa’s two transactivation do-
mains, and/or differential binding of
HIF1a and HIF2a to non-HIF transcription
factors such as c-Myc and Notch (Kaelin
and Ratcliffe, 2008). A second difference
is that HIF1a, but not HIF2a, remains
susceptible to ubiquitinylation in VHL/
cells, implying the existence of additional
HIF1a ubiquitin ligases that do not require
pVHL (Kaelin, 2008). Finally, synthesis of
HIF1a is more sensitive to rapalogs, which
inhibit the mTOR-containing TORC1
complex, than is the synthesis of HIF2a
(Toschi et al., 2008). Instead, synthesis
of HIF2a appears to be controlled by
the mTOR-containing TORC2 complex,
which is relatively insensitive to rapalogs.
VHL/ renal carcinoma cell lines pro-
duce either HIF1a and HIF2a or HIF2a
alone. Moreover, examination of preneo-
plastic lesions in kidneys from VHL pa-
tients indicates that HIF activation is an
early event, with the appearance of HIF2a
correlating with increased evidence of
transformation (Mandriota et al., 2002).
Importantly, overproduction of HIF2a (but
not HIF1a) is sufficient to override pVHL’sDecember 9, 2008 ª2008 Elsevier Inc. 423
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pVHL targets HIFa for proteasomal degradation. Accordingly, tumors with wild-type pVHL have low levels
of HIFa. pVHL-defective tumors can be subdivided based on whether they accumulate both HIF1a and
HIF2a (H1H2) or HIF2a alone (H2). In the former, HIF1a antagonizes c-Myc. In the latter, this antagonism
is lost and c-Myc activity is therefore increased.ability to suppress VHL/ renal carci-
noma tumor growth in nude mouse assays
(Kondo et al., 2002; Maranchie et al.,
2002). Conversely, silencing HIF2a is suf-
ficient to impair VHL/ renal carcinoma
tumor growth in vivo (Kondo et al., 2003).
These results suggest that downregula-
tion of HIF2a is both necessary and suffi-
cient for pVHL to suppress renal carci-
noma growth. Moreover, deregulation of
HIF2a appears to be both necessary and
sufficient for the development of pathol-
ogy in genetically engineered mice lacking
pVHL in various organs (Kim et al., 2006;
Rankin et al., 2008). Collectively, these re-
sults suggest that HIF2a, rather than the
canonical HIFa family member HIF1a,
drives the development of VHL/ renal
carcinomas.
The observations outlined above, how-
ever, left open the question of whether the
differences between HIF1a and HIF2a
observed in cell lines and mouse models
would play out in clear cell carcinomas
arising in patients. In this issue of Cancer
Cell, Gordan and coworkers studied
over 160 sporadic ccRCCs. As expected,
they found that the majority of these tu-
mors were pVHL defective. Interestingly,
these tumors could be subdivided into
two distinct subtypes based on immuno-
histochemical assays and mRNA profiling
(Figure 1). One subtype was character-
ized by overproduction of both HIF1a424 Cancer Cell 14, December 9, 2008 ª200and HIF2a (‘‘H1H2’’ tumors), and the other
by exclusive production of HIF2a (‘‘H2’’)
(Figure 1). The H2 tumors were associated
with enhanced c-Myc activity and en-
hanced cellular proliferation relative to
H1H2 tumors, irrespective of stage, in
keeping with the idea that HIF1a antago-
nizes c-Myc in vivo. H2 tumors also dis-
played increased expression of genes
involved in DNA repair, which was associ-
ated with decreased levels of endogenous
DNA damage and fewer genomic copy
number changes. Consistent with cell cul-
ture studies, H1H2 tumors were asso-
ciated with increased expression of glyco-
lytic genes relative to H2 tumors. In
addition, proliferation of H1H2 tumors, in
contrast to H2 tumors, appeared to be
driven by increased activity of TORC1, as
determined by phospho-S6 staining, and
MAPK activity, as determined by phos-
pho-ERK staining.
These findings are important for several
reasons. First, they solidify the impor-
tance of HIF2a in human renal carcino-
genesis. Interestingly, increased expres-
sion of HIF2a has been noted in a variety
of nonrenal tumors as well, despite its
more restricted expression in normal tis-
sues. In addition, replacement of HIF1a
with HIF2a in murine embryonic stem cells
promotes their ability to form teratomas
in vivo (Covello et al., 2005). Therefore,
the role of HIF2a as an oncoprotein might8 Elsevier Inc.extend beyond VHL/ renal carcinomas.
Second, they suggest that there are two
biologically distinct types of VHL/ renal
carcinomas: those that produce HIF1a
and those that do not. It will be of interest
to determine whether the presence of
HIF1a has predictive value with respect
to response to therapy, such as therapy
with VEGF inhibitors and rapalogs, and
prognostic value with respect to natural
history. It will also be of interest to deter-
mine whether the absence of HIF1a in
H2 tumors reflects a cell-of-origin issue or
perhaps genetic (or epigenetic) changes
that occurred during tumor progression.
Indeed, the current study by Gordan
et al. raises the somewhat heretical possi-
bility that HIF1a acts as a tumor suppres-
sor in the context ofVHL/ ccRCC. In any
event, future kidney cancer clinical trials,
especially those that directly or indirectly
take aim at HIF, would be well advised
to consider the presence or absence of
HIF1a as a potential confounder.
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